mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-24. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
=== Differential diagnosis === Other diseases have similar characteristics to Treacher Collins syndrome. In the differential diagnosis, one should consider the acrofacial dysostoses. The facial appearance resembles that of Treacher Collins syndrome, but additional limb abnormalities occur in those persons. Examples of these diseases are Nager syndrome and Miller syndrome. The oculoauriculovertebral spectrum should also be considered in the differential diagnosis. An example is hemifacial microsomia, which primarily affects development of the ear, mouth, and mandible. This anomaly may occur bilaterally. Another disease which belongs to this spectrum is Goldenhar syndrome, which includes vertebral abnormalities, epibulbar dermoids and facial deformities.
Among the earliest reports of MOF-based catalysis was the cyanosilylation of aldehydes by a 2D MOF (layered square grids) of formula Cd(4,4′-bpy)2(NO3)2. This investigation centered mainly on size- and shape-selective clathration. A second set of examples was based on a two-dimensional, square-grid MOF containing single Pd(II) ions as nodes and 2-hydroxypyrimidinolates as struts. Despite initial coordinative saturation, the palladium centers in this MOF catalyze alcohol oxidation, olefin hydrogenation, and Suzuki C–C coupling. At a minimum, these reactions necessarily entail redox oscillations of the metal nodes between Pd(II) and Pd(0) intermediates accompanying by drastic changes in coordination number, which would certainly lead to destabilization and potential destruction of the original framework if all the Pd centers are catalytically active. The observation of substrate shape- and size-selectivity implies that the catalytic reactions are heterogeneous and are indeed occurring within the MOF. Nevertheless, at least for hydrogenation, it is difficult to rule out the possibility that catalysis is occurring at the surface of MOF-encapsulated palladium clusters/nanoparticles (i.e., partial decomposition sites) or defect sites, rather than at transiently labile, but otherwise intact, single-atom MOF nodes. "Opportunistic" MOF-based catalysis has been described for the cubic compound, MOF-5.
The frequency of codons, also known as codon usage bias, can vary from species to species with functional implications for the control of translation. The codon varies by organism; for example, most common proline codon in E. coli is CCG, whereas in humans this is the least used proline codon.
I know you need funds. We understand that and our opinion is that you should have the opportunity to rebuild your country. But we have no opinion on the Arab-Arab conflicts, like your border disagreement with Kuwait ... Frankly, we can only see that you have deployed massive troops in the south. Normally that would not be any of our business. But when this happens in the context of what you said on your national day, then when we read the details in the two letters of the Foreign Minister, then when we see the Iraqi point of view that the measures taken by the UAE and Kuwait is, in the final analysis, parallel to military aggression against Iraq, then it would be reasonable for me to be concerned. Saddam stated that he would attempt last-ditch negotiations with the Kuwaitis but Iraq "would not accept death." According to Glaspie's own account, she stated in reference to the precise border between Kuwait and Iraq, "... that she had served in Kuwait 20 years before; 'then, as now, we took no position on these Arab affairs'." Glaspie similarly believed that war was not imminent.
Sources: en.wikipedia.org
== Industry applications == The liquid chromatography marketplace is incredibly diverse. Five to ten firms are consistently market leaders, yet nearly half of the market is made up of small, fragmented companies. This section of the report will focus on the roles that a few companies have had in bringing monolith column technologies to the commercial market. In 1998, start-up biotechnology company BIA Separations of Ljubljana, Slovenia, came into being. The technology was originally developed by Tatiana Tennikova and Frantisek Svec during a collaboration between their respective institutes. The patent for these columns was acquired by BIA Separations and Ales Podgornik and Milos Barut developed the first commercially available monolith column in the form of a short disc encapsulated in a plastic housing. Trademarked CIM, BIA Separations has since introduced full lines of reversed-phase, normal-phase, ion-exchange, and affinity polymeric monoliths. Ales Podgornik and Janez Jancar then went on to develop large scale tube monolithic columns for industrial use. The largest column currently available is 8L. In May 2008, LC instrumentation powerhouse Agilent technologies agreed to market BIA Separations’ analytical columns based on monolith technology. Agilent's commercialized the columns with strong and weak ion exchange phases and Protein A in September 2008 when they unveiled their new Bio-Monolith product line at the BioProcess International conference.
In 2009 they showed that the same simple building blocks allow access, via phosphate controlled nucleobase elaboration, to 2',3'-cyclic pyrimidine nucleotides directly, which can polymerize into RNA. Similar photo-sanitization can create pyrimidine-2',3'-cyclic phosphates.
'High-throughput quantitative bioanalysis by LC/MS/MS', Volume 14, Issue 6, Oct 2000, Pages: 422 - 429, Jemal M. Cited 178 times 'Analytical Chemistry and Biochemistry of D-Amino Acids', Volume 10, Issue 6, Nov-Dec 1996, Pages: 303–312, Imai K, Fukushima T, Santa T, et al. Cited 79 times 'Fluorogenic and fluorescent labeling reagents with a benzofurazan skeleton', Volume 15, Issue 5, Aug 2001, Pages: 295–318, Uchiyama S, Santa T, Okiyama N, et al. Cited 74 times
Sources: en.wikipedia.org
In 1876, French engineer Charles Tellier bought the ex-Elder-Dempster 690 tons cargo ship Eboe and fitted a Methyl-ether refrigerating plant of his design. The ship was renamed Le Frigorifique and successfully imported a cargo of refrigerated meat from Argentina. However the machinery could be improved and in 1877 another refrigerated ship called Paraguay with a refrigerating plant improved by Ferdinand Carré was put into service on the South American run. In 1879, Henry Bell (1848–1931) and John Bell (1850–1929) of Scotland and Joseph James Coleman FRSE (1838–1888) of Scotland completed the Bell–Coleman dense-air machine on the Anchor liner Circassia, which successfully brought a cargo of chilled beef from the US to London. In 1880, Strathleven, equipped with a Bell–Coleman air machine and loaded with successfully shipped beef, mutton, butter and kegs, sailed from Melbourne, Australia, to London—a nine-week voyage of about 15,000 miles (24,000 km). In 1881, Alfred Seale Haslam (1844–1927) of England equipped the liner Orient with Haslam refrigeration compressors. He bought the Bell–Coleman dense-air patents in 1878 and eventually equipped four hundred plants and ships with Bell-Coleman machines. By 1899, refrigerated fruit ship traffic to the US reached 90,000 tons per year. By 1890, after acquiring the patent rights of Franz Windhausen's CO2-compression refrigeration system, the J & E Hall company installed the first marine CO2 refrigerator system on the Nelson Line ship Highland Chief.
social: criminal groups seek to develop social control in relation to particular communities; economic: seek to exert influence by means of corruption and by coercion of legitimate and illegitimate praxis; and, political: criminal groups use corruption and violence to attain power and status. Contemporary organized crime may be very different from traditional Mafia style, particularly in terms of the distribution and centralization of power, authority structures and the concept of 'control' over one's territory and organization. There is a tendency away from centralization of power and reliance upon family ties towards a fragmentation of structures and informality of relationships in crime groups. Organized crime most typically flourishes when a central government and civil society is disorganized, weak, absent or untrustworthy. This may occur in a society facing periods of political, economic or social turmoil or transition, such as a change of government or a period of rapid economic development, particularly if the society lacks strong and established institutions and the rule of law. The dissolution of the Soviet Union and the Revolutions of 1989 in Eastern Europe that saw the downfall of the Communist Bloc created a breeding ground for criminal organizations. The newest growth sectors for organized crime are identity theft and online extortion. These activities are troubling because they discourage consumers from using the Internet for e-commerce.
== Education == Frank completed her M.D. and Ph.D. in biochemistry at the University of Pennsylvania. She completed a clinical pathology residency at the Brigham and Women's Hospital. During her postdoctoral research fellowship in immunology, she focused on V(D)J recombination in developing lymphocytes in the Howard Hughes Medical Institute laboratory of Frederick Alt at the Boston Children's Hospital. As a faculty member, her studies included DNA repair mechanisms relevant to both cancer and immunology, followed by microbiological investigations of Staphylococcus aureus and enterobacteriaceae.
=== Metabolism: 20th century – present === One of the most prolific of these modern biochemists was Hans Krebs who made huge contributions to the study of metabolism. Krebs was a student of extremely important Otto Warburg, and wrote a biography of Warburg by that title in which he presents Warburg as being educated to do for biological chemistry what Fischer did for organic chemistry. Which he did. Krebs discovered the urea cycle and later, working with Hans Kornberg, the citric acid cycle and the glyoxylate cycle. These discoveries led to Krebs being awarded the Nobel Prize in physiology in 1953, which was shared with the German biochemist Fritz Albert Lipmann who also codiscovered the essential cofactor coenzyme A.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.